Skip to main content

Advertisement

Table 1 Demographic and clinical characteristics associated with the odds of being seen at the smoking cessation clinic at KHCC in a sample of 3403 Jordanian cancer patients who smoke (column totals presented). A total of 717 cancer patients were seen at the clinic while 2686 were not

From: Smoking cessation care can translate to lower hazard of death in the short-run in cancer patients - a retrospective cohort study to demonstrate the value of smoking cessation services within the treatment phase of cancer

Variable: Proportion seen at the clinic (n) Unadjusted odds ratio of being seen (95% CI) Adjusted odds ratio (of being seen)
Gender
 Males (N = 2454) 23.5% (n = 576) Reference group Reference group
 Females (N = 949) 14.9% (n = 141) 0.59 (0.46–0.70) 0.49 (0.38–0.63)
Age at diagnosis
 18–30 (N = 278) 21.9% (n = 61) Reference group Reference group
 31–40 (N = 491) 17.5% (n = 86) 0.76 (0.52–1.1) 0.89 (0.57–1.4)
 41–50 (N = 776) 24.4% (n = 189) 1.1 (0.83–1.6) 1.3 (0.82–1.9)
 51–60 (N = 860) 24.2% (n = 208) 1.1 (0.82–1.6) 1.1 (0.73–1.7)
 61–70 (N = 675) 19.1% (n = 129) 0.84 (0.60–1.2) 0.78 (0.49–1.2)
  > 70 (N = 323) 13.6% (n = 44) 0.56 (0.37–0.86) 0.49 (0.29–0.85)
Diagnosis year
 2009 (N = 256) 14.8% (n = 38) Reference group Reference group
 2010 (N = 382) 13.1% (n = 50) 0.86 (0.55–1.4) 0.85 (0.53–1.4)
 2011 (N = 378) 14.3% (n = 54) 0.96 (0.61–1.5) 0.94 (0.60–1.5)
 2012 (N = 329) 13.4% (n = 44) 0.89 (0.55–1.4) 0.86 (0.53–1.4)
 2013 (N = 416) 15.9% (n = 66) 1.1 (0.70–1.7) 1.0 (0.66–1.6)
 2014 (N = 492) 20.7% (n = 102) 1.5 (0.99–2.3) 1.4 (0.91–2.1)
 2015 (N = 572) 28.5% (n = 163) 2.3 (1.5–3.4) 2.4 (1.6–3.6)
 2016 (N = 578) 34.6% (n = 200) 3.0 (2.1–4.5) 3.3 (2.2–4.9)
Marital status
 Married (N = 2825) 21.3% (n = 601) Reference group Reference group
 Single (N = 378) 18.5% (n = 70) 0.84 (0.64–1.1) 0.88 (0.62–1.3)
 Separated/divorced/widowed (N = 200) 23.0% (n = 46) 1.1 (0.79–1.6) 1.4 (0.93–2.0)
Geographic area
 Central (N = 2860) 21.4% (n = 613) Reference group Reference group
 North (N = 350) 19.1% (n = 67) 0.87 (0.66–1.1) 0.74 (0.55–0.99)
 South (N = 192) 19.3% (n = 37) 0.88 (0.60–1.3) 0.80 (0.55–1.2)
Tumor type and relation to tobacco
 Solid, tobacco-relateda (N = 851) 25.5% (n = 217) Reference group Reference group
 Solid, tobacco-related (other)b (N = 827) 20.1% (n = 166) 0.73 (0.58–0.92) 0.57 (0.43–0.75)
 Solid, not tobacco-related (N = 1186) 16.8% (n = 199) 0.59 (0.48–0.73) 0.51 (0.38–0.69)
 Hematological, tobacco-related (N = 60) 13.3% (n = 8) 0.45 (0.21–0.96) 0.52 (0.23–1.2)
 Hematological, not tobacco-related (N = 478) 26.6% (n = 127) 1.1 (0.82–1.4) 1.1 (0.8–1.5)
Stage
 In-situ (N = 107) 29.9% (n = 32) 1.6 (1.03–2.5) 1.7 (1.03–2.8)
 Local (N = 797) 20.8% (n = 166) Reference group Reference group
 Regional (N = 1229) 22.8% (n = 280) 1.1 (0.90–1.4) 0.95 (0.74–1.2)
 Distant or unstaged (N = 1270) 18.8% (n = 239) 0.89 (0.71–1.1) 0.54 (0.40–0.71)
Received chemotherapy
 No (N = 1027) 19.6% (n = 201) Reference group Reference group
 Yes (N = 2376) 21.7% (n = 516) 1.14 (0.95–1.5) 1.4 (1.1–1.8)
Received surgery
 No (N = 2153) 21.0% (n = 451) Reference group Reference group
 Yes (N = 1250) 21.3% (n = 266) 1.0 (0.86–1.2) 1.0 (0.80–1.3)
Received radiation
 No (N = 1867) 21.2% (n = 395) Reference group Reference group
 Yes (N = 1536) 21.0% (n = 322) 0.99 (0.84–1.2) 0.96 (0.78–1.2)
Received hormonal therapy
 No (N = 2944) 21.8% (n = 643) Reference group Reference group
 Yes (N = 459) 16.1% (n = 74) 0.69 (0.53–0.90) 1.3 (0.94–1.9)
Received immunotherapy
 No (N = 3331) 20.9% (n = 696) Reference group Reference group
 Yes (N = 72) 29.2% (n = 21) 1.6 (0.93–2.6) 1.6 (0.92–3.0)
Received BMT
 No (N = 3283) 20.9% (n = 687) Reference group Reference group
 Yes (N = 120) 25.0% (n = 30) 1.3 (0.83–1.9) 1.6 (0.99–2.5)
Have diabetes
 No (N = 2826) 20.7% (n = 586) Reference group Reference group
 Yes (N = 577) 22.7% (n = 131) 1.1 (0.91–1.4) 0.99 (0.77–1.3)
Have respiratory disease
 No (N = 3122) 20.9% (n = 653) Reference group Reference group
 Yes (N = 281) 22.8% (n = 64) 1.1 (0.83–1.5) 0.98 (0.70–1.4)
Have cardio- or cerebrovascular disease
 No (N = 2464) 20.5% (n = 506) Reference group Reference group
 Yes (N = 939) 22.5% (n = 211) 1.1 (0.94–1.3) 1.1 (0.90–1.4)
  1. a Head, neck, respiratory, esophageal
  2. b Colorectal, cervical, pancreatic, urinary, stomach and liver
  3. p < 0.05